StockNews.com Upgrades Cyclacel Pharmaceuticals (NASDAQ:CYCC) to “Hold”

StockNews.com upgraded shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) from a sell rating to a hold rating in a research report report published on Tuesday.

Separately, Roth Mkm reduced their target price on Cyclacel Pharmaceuticals from $21.00 to $11.00 and set a buy rating on the stock in a report on Friday, May 3rd.

Cyclacel Pharmaceuticals Trading Up 2.4 %

CYCC stock opened at $1.69 on Tuesday. The firm has a market capitalization of $2.47 million, a PE ratio of -0.08 and a beta of 0.58. Cyclacel Pharmaceuticals has a 1-year low of $1.30 and a 1-year high of $13.20. The business’s 50 day simple moving average is $2.06 and its 200 day simple moving average is $2.53.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last issued its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($2.27) EPS for the quarter, beating analysts’ consensus estimates of ($4.93) by $2.66. Cyclacel Pharmaceuticals had a negative return on equity of 1,009.04% and a negative net margin of 4,401.34%. The firm had revenue of $0.03 million for the quarter. During the same period in the prior year, the company earned ($7.05) earnings per share. As a group, sell-side analysts predict that Cyclacel Pharmaceuticals will post -4.93 EPS for the current fiscal year.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.